STSA-1301 subcutaneous injection

DRUG2 trials

Sponsors

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Jiangsu BioJeTay Biotechnology Co., Ltd.

Conditions

Primary Immune ThrombocytopeniaPrimary Immune Thrombocytopenia (ITP)

Phase 1

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

CompletedNCT06148389

Staidson (Beijing) Biopharmaceuticals Co., LtdPrimary Immune Thrombocytopenia

Start: 2023-11-16End: 2024-04-03Updated: 2024-08-12

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

RecruitingNCT06929299

Jiangsu BioJeTay Biotechnology Co., Ltd.Primary Immune Thrombocytopenia (ITP)

Start: 2025-05-12End: 2026-09-01Target: 56Updated: 2026-08-12